Literature DB >> 19434472

Phyllodes tumor of the breast: an update.

Gary M K Tse1, Yun Niu, Hui-Juan Shi.   

Abstract

Phyllodes tumor is an uncommon biphasic breast tumor, with the ability to recur and metastasize, and it behaves biologically like a stromal neoplasm. Traditionally, phyllodes tumors are graded by the use of a set of histologic data into benign, borderline, and malignant. In most series, all phyllodes tumors may recur, but only the borderline and malignant phyllodes tumors metastasize. On the basis of histologic features, prediction of behavior is difficult. The expression of many biological markers, including p53, hormone receptors, proliferation markers, angiogenesis group of markers, c-kit, CD10 and epidermal growth factor receptor have been explored, and many have been shown to be variably expressed, depending on the grade of the tumor. These markers are, however, of limited value in predicting the behavior of the tumor. Recently investigators have reported a plethora of genetic changes in phyllodes tumors, the most consistent of which seems to be 1q gain by comparative genomic hybridization. Some candidate genes have been mapped to various sites, and preliminary data suggest that some of these changes may be related to recurrence. It is foreseeable that more exciting data will be generated to help us to understand the etiology and pathogenesis of phyllodes tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434472     DOI: 10.1007/s12282-009-0114-z

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  22 in total

1.  Fibroadenoma versus phyllodes tumor: distinguishing factors in patients diagnosed with fibroepithelial lesions after a core needle biopsy.

Authors:  Cholatip Wiratkapun; Pawat Piyapan; Panuwat Lertsithichai; Noppadol Larbcharoensub
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

2.  Five-Year Disease-Free Follow-Up of a Borderline Breast Phyllodes Tumor in a 15-year-old Patient.

Authors:  Sertaç Ata Güler; M Ümit Uğurlu; Bahadır M Güllüoğlu
Journal:  J Breast Health       Date:  2015-07-01

3.  Phyllodes tumours of the breast: radiological presentation, management and follow-up.

Authors:  E McCarthy; J Kavanagh; Y O'Donoghue; E McCormack; C D'Arcy; S A O'Keeffe
Journal:  Br J Radiol       Date:  2014-10-01       Impact factor: 3.039

4.  Malignant phyllodes tumors of the breast: a study in clinical practice.

Authors:  James Majeski; Jason Stroud
Journal:  Int Surg       Date:  2012 Apr-Jun

5.  Invasive cribriform carcinoma arising in malignant phyllodes tumor of breast: a case report.

Authors:  Yoomi Choi; Kyoung Yul Lee; Min Hye Jang; Hyesil Seol; Sung-Won Kim; So Yeon Park
Journal:  Korean J Pathol       Date:  2012-04-25

6.  Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience.

Authors:  Jerzy Władysław Mituś; Paweł Blecharz; Marian Reinfuss; Jan Kanty Kulpa; Piotr Skotnicki; Wojciech Maria Wysocki
Journal:  Med Sci Monit       Date:  2013-12-19

7.  Breast-conserving surgery is contraindicated for recurrent giant multifocal phyllodes tumours of breast.

Authors:  Elroy P Weledji; George Enow-Orock; Marcelin N Ngowe; Leopold Aminde
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

8.  Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.

Authors:  J W Mituś; P Blecharz; T Walasek; M Reinfuss; J Jakubowicz; J Kulpa
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

9.  Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast.

Authors:  Xiaolong Feng; Lin Zhao; Honghong Shen; Xiaozhen Liu; Yang Yang; Shuhua Lv; Yun Niu
Journal:  Oncotarget       Date:  2017-05-16

Review 10.  Breast malignant phyllodes tumor with rare pelvic metastases and long-term overall survival: A case report and literature review.

Authors:  Jinlan Shan; Shizhen Zhang; Zhen Wang; Yanbiao Fu; Ling Li; Xiaochen Wang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.